Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness

Author(s): Jonathan Hamill , Jaime Hallak , Serdar M. Dursun , Glen Baker* .

Journal Name: Current Neuropharmacology

Volume 17 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Ayahuasca, a traditional Amazonian decoction with psychoactive properties, is made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) and leaves of the Psychotria viridis bush (supplying the hallucinogen N,N-dimethyltryptamine, DMT). Originally used by indigenous shamans for the purposes of spirit communication, magical experiences, healing, and religious rituals across several South American countries, ayahuasca has been incorporated into folk medicine and spiritual healing, and several Brazilian churches use it routinely to foster a spiritual experience. More recently, it is being used in Europe and North America, not only for religious or healing reasons, but also for recreation.

Objective: To review ayahuasca’s behavioral effects, possible adverse effects, proposed mechanisms of action and potential clinical uses in mental illness.

Method: We searched Medline, in English, using the terms ayahuasca, dimethyltryptamine, Banisteriopsis caapi, and Psychotria viridis and reviewed the relevant publications.

Results: The following aspects of ayahuasca are summarized: Political and legal factors; acute and chronic psychological effects; electrophysiological studies and imaging; physiological effects; safety and adverse effects; pharmacology; potential psychiatric uses.

Conclusion: Many years of shamanic wisdom have indicated potential therapeutic uses for ayahuasca, and several present day studies suggest that it may be useful for treating various psychiatric disorders and addictions. The side effect profile appears to be relatively mild, but more detailed studies need to be done. Several prominent researchers believe that government regulations with regard to ayahuasca should be relaxed so that it could be provided more readily to recognized, credible researchers to conduct comprehensive clinical trials.

Keywords: Ayahuasca, hallucinogens, N, N-dimethyltryptamine (DMT), Banisteriopsis caapi, Psychotria viridis, monoamine oxidase (MAO).

[1]
Halpern, J.H.; Sherwood, A.R.; Passie, T.; Blackwell, K.C.; Ruttenber, A.J. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med. Sci. Monit., 2008, 14(8), SR15-SR22.
[PMID: 18668010]
[2]
Kjellgren, A.; Eriksson, A.; Norlander, T. Experiences of encounters with ayahuasca--“the vine of the soul. J. Psychoactive Drugs, 2009, 41(4), 309-315.
[http://dx.doi.org/10.1080/02791072.2009. 10399767] [PMID: 20235436]
[3]
Gable, R.S. Risk assessment of ritual use of oral N,Ndimethyltryptamine (DMT) and harmala alkaloids Addiction; M.J, Winkelman; T.B, Roberts, Eds.; Psychedelic Medicine (Vol 2): New evidence for hallucinogenic substances as treatments, 2007, 102, (1), 24-34.
[4]
Callaway, J.C.; McKenna, D.J.; Grob, C.S.; Brito, G.S.; Raymon, L.P.; Poland, R.E.; Andrade, E.N.; Andrade, E.O.; Mash, D.C. Pharmacokinetics of Hoasca alkaloids in healthy humans. J. Ethnopharmacol., 1999, 65(3), 243-256.
[http://dx.doi.org/10.1016/S0378-8741(98)00168-8] [PMID: 10404423]
[5]
Mabit, J. Ayahuasca in the treatment of addictions. Psychedelic Medicine (Vol 2): New Evidence for Hallucinogenic Substances as Treatments, 2007, 87. M.J, Winkelman; T.B, Roberts Praeger Publishers Westport, CT(105).
[6]
Dobkin de Rios, M. Ayahuasca--the healing vine. Int. J. Soc. Psychiatry, 1971, 17(4), 256-269.
[http://dx.doi.org/10.1177/002076407101700402] [PMID: 5145130]
[7]
Dos Santos, R.G.; Osório, F.L.; Crippa, J.A.S.; Hallak, J.E. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Br. J. Psychiatry, 2016, 38(1), 65-72.
[http://dx.doi.org/10.1590/1516-4446-2015-1701] [PMID: 27111702]
[8]
Grob, C.S.; McKenna, D.J.; Callaway, J.C.; Brito, G.S.; Neves, E.S.; Oberlaender, G.; Saide, O.L.; Labigalini, E.; Tacla, C.; Miranda, C.T.; Strassman, R.J.; Boone, K.B. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J. Nerv. Ment. Dis., 1996, 184(2), 86-94.
[http://dx.doi.org/10.1097/00005053-199602000-00004] [PMID: 8596116]
[9]
Desmarchelier, C.; Gurni, A.; Ciccia, G.; Giulietti, A.M. Ritual and medicinal plants of the Ese’ejas of the Amazonian rainforest (Madre de Dios, Perú). J. Ethnopharmacol., 1996, 52(1), 45-51.
[http://dx.doi.org/10.1016/0378-8741(96)01390-6] [PMID: 8733119]
[10]
McKenna, D.J. The healing vine: Ayahuasca as medicine in the 21st century. Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments; Winkelman, M.J; Roberts, T.B., Ed.; Praeger Publishers, 2007, Vol. 1, pp. 21-44.
[11]
Barbosa, P.C.R.; Giglio, J.S.; Dalgalarrondo, P. Altered states of consciousness and short-term psychological after-effects induced by the first time ritual use of ayahuasca in an urban context in Brazil. J. Psychoactive Drugs, 2005, 37(2), 193-201.
[http://dx.doi.org/ 10.1080/02791072.2005.10399801] [PMID: 16149333]
[12]
Labate, B.C. Consumption of ayahuasca by children and pregnant women: medical controversies and religious perspectives. J. Psychoactive Drugs, 2011, 43(1), 27-35.
[http://dx.doi.org/10.1080/02791072.2011.566498] [PMID: 21615005]
[13]
Riba, J.; Valle, M.; Urbano, G.; Yritia, M.; Morte, A.; Barbanoj, M.J. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J. Pharmacol. Exp. Ther., 2003, 306(1), 73-83.
[http://dx.doi.org/10.1124/jpet.103.049882] [PMID: 12660312]
[14]
Lemlij, M. Primitive group treatment. Psychiatr. Clin. (Basel), 1978, 11(1), 10-14.
[PMID: 704949]
[15]
Cakic, V.; Potkonyak, J.; Marshall, A. Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users. Drug Alcohol Depend., 2010, 111(1-2), 30-37.
[http://dx.doi.org/10.1016/j.drugalcdep.2010.03.015] [PMID: 20570058]
[16]
Cardenas, A.V.; Gomez, A.P. Urban use of yaje (ayahuasca) in Colombia. Adicciones, 2004, 16, 323-334.
[17]
Barbosa, P.C.R.; Cazorla, I.M.; Giglio, J.S.; Strassman, R. A six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naïve subjects. J. Psychoactive Drugs, 2009, 41(3), 205-212.
[http://dx.doi.org/10.1080/02791072.2009.10400530] [PMID: 19999673]
[18]
Fiedler, L.; Jungaberle, H.; Verres, R. Motives for the consumption of psychoactive substances demonstrated in the example of the use of ayahuasca in the Santo Daime community. Zeitschr Fur Medizin Psychol., 2011, 20, 137-144.
[19]
Holman, C. Surfing for a shaman: Analyzing an ayahuasca website. Ann. Tour. Res., 2011, 38(1), 90-109.
[http://dx.doi.org/10.1016/j. annals.2010.05.005]
[20]
Fotiou, E. From medicine men to day trippers: Shamanic tourism in Iquitos, Peru. Dissertation Abstracts Int Section A: Humanities and Social .Sci., 2011, 72(1-A), 256.
[21]
Winkelman, M. Drug tourism or spiritual healing? Ayahuasca seekers in Amazonia. J. Psychoactive Drugs, 2005, 37(2), 209-218.
[http://dx.doi.org/10.1080/02791072.2005.10399803] [PMID: 16149335]
[22]
Arrévalo, G. Interview with Guillermo Arrévalo, a Shipibo urban shaman, by Roger Rumrrill. Interview by Roger Rumrrill. J. Psychoactive Drugs, 2005, 37(2), 203-207.
[http://dx.doi.org/ 10.1080/02791072.2005.10399802] [PMID: 16149334]
[23]
Kavenska, V.; Simonova, H. Ayahuasca tourism: participants in shamanic rituals and their personality styles, motivation, benefits and risks. J. Psychoactive Drugs, 47, 351-359. B2015B.
[24]
Balíková, M. Collective poisoning with hallucinogenous herbal tea. Forensic Sci. Int., 2002, 128(1-2), 50-52.
[http://dx.doi.org/10. 1016/S0379-0738(02)00162-7] [PMID: 12208022]
[25]
Shulgin, A.T.; Shulgin, A.; Perrine, D.M. Tihkal: the continuation, 1997.
[26]
Labate, B.C.; Cavnar, C. The expansion of the field of research on ayahuasca: some reflections about the ayahuasca track at the 2010 MAPS “Psychedelic Science in the 21st Century” conference. Int. J. Drug Policy, 2011, 22(2), 174-178.
[http://dx.doi.org/10.1016/j. drugpo.2010.09.002] [PMID: 21051213]
[27]
Araújo, A.M.; Carvalho, F. Bastos, Mde.L.; Guedes de Pinho, P.; Carvalho, M. The hallucinogenic world of tryptamines: an updated review. Arch. Toxicol., 2015, 89(8), 1151-1173.
[http://dx.doi.org/ 10.1007/s00204-015-1513-x] [PMID: 25877327]
[28]
Kowalczuk, A.P.; Łozak, A.; Bachliński, R.; Duszyński, A.; Sakowska, J.; Zjawiony, J.K. Identification challenges in examination of commercial plant material of psychotria viridis. Acta Pol. Pharm., 2015, 72(4), 747-755.
[PMID: 26647632]
[29]
Blainey, M.G. Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society. J. Relig. Health, 2015, 54(1), 287-302.
[http://dx.doi.org/10.1007/s10943-014-9826-2] [PMID: 24477460]
[30]
Tupper, K.W.; Labate, B.C. Plants, psychoactive substances and the international narcotics control board: the control of nature and the nature of control. Human Rights and Drugs., 2012, 2, 17-28.
[31]
Ott, J. Pharmahuasca: human pharmacology of oral DMT plus harmine. J. Psychoactive Drugs, 1999, 31(2), 171-177.
[http://dx.doi.org/10.1080/02791072.1999.10471741] [PMID: 10438001]
[32]
Groisman, A.; de Rios, M.D. Ayahuasca, the U.S. Supreme Court, and the UDV-U.S. government case: Culture, religion, and implications of a legal dispute. Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments; Winkelman, M.J; Roberts, T.B., Ed.; Praeger Publishers: Westport, CT, 2007, pp. 251-269.
[33]
Bullis, R.K. The “vine of the soul” vs. the Controlled Substances Act: implications of the hoasca case. J. Psychoactive Drugs, 2008, 40(2), 193-199.
[http://dx.doi.org/10.1080/02791072.2008. 10400630] [PMID: 18720669]
[34]
Tupper, K.W. Yahuasca, entheogenic education public policy. 2011, (Ph.D, Simon Fraser University, Vancouver, British Columbia, Canada).
[35]
Thomas, G.; Lucas, P.; Capler, N.R.; Tupper, K.W.; Martin, G. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr. Drug Abuse Rev., 2013, 6(1), 30-42.
[http://dx.doi.org/10.2174/15733998113099990003] [PMID: 23627784]
[36]
Anderson, B.T.; Labate, B.C.; Meyer, M.; Tupper, K.W.; Barbosa, P.C.; Grob, C.S.; Dawson, A.; McKenna, D. Statement on ayahuasca. Int. J. Drug Policy, 2012, 23(3), 173-175.
[http://dx.doi.org/ 10.1016/j.drugpo.2012.02.007] [PMID: 22459485]
[37]
Strassman, R. Subjective effects of DMT and the development of the hallucinogen rating scale Newsletter Multidisciplinary Assoc. for Psychedelic Studies,1992, 3(2).
[38]
Bresnick, T.; Levin, R. Phenomenal qualities of ayahuasca ingestion and its relation to fringe consciousness and personality. Consciousness Studies, 2006, 13(9), 5-24.
[39]
Shanon, B. Altered temporality. Consciousness Studies, 2001, 8(1), 35-58.
[40]
Riba, J.; Rodríguez-Fornells, A.; Urbano, G.; Morte, A.; Antonijoan, R.; Montero, M.; Callaway, J.C.; Barbanoj, M.J. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl.), 2001, 154(1), 85-95.
[http://dx.doi.org/10.1007/s002130000606] [PMID: 11292011]
[41]
Beyer, S.V. Singing to the plants: A guide to Mestizo shamanism in the upper Amazon; University of New Mexico Press: Albuquerque, 2009.
[42]
Dos Santos, R.G.; Valle, M.; Bouso, J.C.; Nomdedéu, J.F.; Rodríguez-Espinosa, J.; McIlhenny, E.H.; Barker, S.A.; Barbanoj, M.J.; Riba, J. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. J. Clin. Psychopharmacol., 2011, 31(6), 717-726.
[http://dx.doi.org/10.1097/JCP.0b013e31823607f6] [PMID: 22005052]
[43]
Dos Santos, R.G.; Grasa, E.; Valle, M.; Ballester, M.R.; Bouso, J.C.; Nomdedéu, J.F.; Homs, R.; Barbanoj, M.J.; Riba, J. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl.), 2012, 219(4), 1039-1053.
[http://dx.doi.org/ 10.1007/s00213-011-2434-x] [PMID: 21842159]
[44]
Riba, J.; Rodríguez-Fornells, A.; Barbanoj, M.J. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology (Berl.), 2002, 165(1), 18-28.
[http://dx.doi.org/10.1007/s00213-002-1237-5] [PMID: 12474114]
[45]
Metzner, R. Hallucinogenic drugs and plants in psychotherapy and shamanism. J. Psychoactive Drugs, 1998, 30(4), 333-341.
[http://dx.doi.org/10.1080/02791072.1998.10399709] [PMID: 9924839]
[46]
Strassman, R.J.; Qualls, C.R. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch. Gen. Psychiatry, 1994, 51(2), 85-97.
[http://dx.doi.org/10.1001/archpsyc.1994.03950020009001] [PMID: 8297216]
[47]
Callaway, J.C.; McKenna, D.J.; Grob, C.S.; Brito, G.S.; Raymon, L.P.; Poland, R.E.; Andrade, E.N.; Andrade, E.O.; Mash, D.C. Pharmacokinetics of Hoasca alkaloids in healthy humans. J. Ethnopharmacol., 1999, 65(3), 243-256.
[http://dx.doi.org/10.1016/S0378-8741(98)00168-8] [PMID: 10404423]
[48]
Rhodium Archive. 2009. A Hypothesis of the Mechanisms Underlying Visual Distortions Caused by Psychedelic Drugs. Available at http://www.erowid.org/archive/rhodium/pharmacology/visual distortions.html
[49]
Shanon, B. The antipodes of the mind: charting the phenomenology of the ayahuasca experience; Oxford University Press: Oxford, UK, 2007.
[50]
Cloninger, C.R. A systematic method for clinical description and classification of personality variants. A proposal. Arch. Gen. Psychiatry, 1987, 44(6), 573-588.
[http://dx.doi.org/10.1001/archpsyc.1987.01800180093014] [PMID: 3579504]
[51]
Fábregas, J.M.; González, D.; Fondevila, S.; Cutchet, M.; Fernández, X.; Barbosa, P.C.R.; Alcázar-Córcoles, M.Á.; Barbanoj, M.J.; Riba, J.; Bouso, J.C. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend., 2010, 111(3), 257-261.
[http://dx.doi.org/10.1016/j.drugalcdep.2010.03.024] [PMID: 20554400]
[52]
Harris, R.; Gurel, L. A study of ayahuasca use in North America. J. Psychoactive Drugs, 2012, 44(3), 209-215.
[http://dx.doi.org/10. 1080/02791072.2012.703100] [PMID: 23061320]
[53]
Barbosa, P.C.R.; Strassman, R.J.; da Silveira, D.X.; Areco, K.; Hoy, R.; Pommy, J.; Thoma, R.; Bogenschutz, M. Psychological and neuropsychological assessment of regular hoasca users. Compr. Psychiatry, 2016, 71, 95-105.
[http://dx.doi.org/10.1016/j.comppsych.2016.09.003] [PMID: 27653781]
[54]
Frecska, E.; Móré, C.E.; Vargha, A.; Luna, L.E. Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. J. Psychoactive Drugs, 2012, 44(3), 191-199.
[http://dx.doi.org/10.1080/02791072.2012.703099] [PMID: 23061318]
[55]
Soler, J.; Elices, M.; Franquesa, A.; Barker, S.; Friedlander, P.; Feilding, A.; Pascual, J.C.; Riba, J. Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. Psychopharmacology (Berl.), 2016, 233(5), 823-829.
[http://dx.doi.org/10.1007/s00213-015-4162-0] [PMID: 26612618]
[56]
Bouso, J.C.; González, D.; Fondevila, S.; Cutchet, M.; Fernández, X.; Ribeiro Barbosa, P.C.; Alcázar-Córcoles, M.Á.; Araújo, W.S.; Barbanoj, M.J.; Fábregas, J.M. Riba, J. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One, 2012, 7(8), e42421-e13.
[http://dx.doi.org/10.1371/journal.pone.0042421] [PMID: 22905130]
[57]
Kuypers, K.P.C.; Riba, J.; de la Fuente Revenga, M.; Barker, S.; Theunissen, E.L.; Ramaekers, J.G. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology (Berl.), 2016, 233(18), 3395-3403.
[http://dx.doi.org/10.1007/s00213-016-4377-8] [PMID: 27435062]
[58]
Burton, J.C. Psychological variables predicting intensity and contents of consciousness during ayahuasca experiences: A pilot study. Dissertation Abstracts Int: Section B: Sci and Engineering, 2010, 70(9-B), 5882
[59]
Loizaga-Velder, A.; Verres, R. Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence--qualitative results. J. Psychoactive Drugs, 2014, 46(1), 63-72.
[http://dx.doi.org/10.1080/02791072.2013.873157] [PMID: 24830187]
[60]
Cavnar, C. The effects of participation in ayahuasca rituals on gay and lesbian identity. J. Psychoactive Drugs, 2014, 46, 252-260.
[http://dx.doi.org/10.1080/02791072.2014.920117] [PMID: 25052884]
[61]
Riba, J.; Anderer, P.; Morte, A.; Urbano, G.; Jané, F.; Saletu, B.; Barbanoj, M.J. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br. J. Clin. Pharmacol., 2002, 53(6), 613-628.
[http://dx.doi.org/10.1046/j.1365-2125.2002.01609.x] [PMID: 12047486]
[62]
dos Santos, R.G. Safety and side effects of ayahuasca in humans--an overview focusing on developmental toxicology. J. Psychoactive Drugs, 2013, 45(1), 68-78.
[http://dx.doi.org/10.1080/02791072. 2013.763564] [PMID: 23662333]
[63]
Riba, J.; Anderer, P.; Jané, F.; Saletu, B.; Barbanoj, M.J. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology, 2004, 50(1), 89-101.
[http://dx.doi.org/10.1159/000077946] [PMID: 15179026]
[64]
Schenberg, E.E.; Alexandre, J.F.M.; Filev, R.; Cravo, A.M.; Sato, J.R.; Muthukumaraswamy, S.D.; Yonamine, M.; Waguespack, M.; Lomnicka, I.; Barker, S.A.; da Silveira, D.X. Acute blphasic effects of ayahuasca. PLoS One, 2015, 10(9), e0137202.
[http://dx.doi.org/ 10.1371/journal.pone.0137202] [PMID: 26421727]
[65]
Don, N.S.; McDonough, B.E.; Moura, G.; Warren, C.A.; Kawanishi, K.; Tomita, H.; Tachibana, Y.; Böhlke, M.; Farnsworth, N.R. Effects of Ayahuasca on the human EEG. Phytomedicine, 1998, 5(2), 87-96.
[http://dx.doi.org/10.1016/S0944-7113(98)80003-2] [PMID: 23195759]
[66]
Stuckey, D.E. EEG gamma coherence and other correlates of subjective reports during ayahuasca experiences. Dissertation Abstracts Int: Section B: Sci and Engineering, 2005, 66(1-B), 610.
[67]
Valle, M.; Maqueda, A.E.; Rabella, M.; Rodríguez-Pujadas, A.; Antonijoan, R.M.; Romero, S.; Alonso, J.F.; Mañanas, M.À.; Barker, S.; Friedlander, P.; Feilding, A.; Riba, J. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur. Neuropsychopharmacol., 2016, 26(7), 1161-1175.
[http://dx.doi.org/10.1016/j.euroneuro. 2016.03.012] [PMID: 27039035]
[68]
Alonso, J.F.; Romero, S.; Mañanas, M.A.; Riba, J. Serotonergic psychedelics temporarily modify information transfer in humans. Int. J. Neuropsychopharmacol., 2015, 18(8), pyv039.
[http://dx.doi.org/10.1093/ijnp/pyv039] [PMID: 25820842]
[69]
Riba, J.; Romero, S.; Grasa, E.; Mena, E.; Carrió, I.; Barbanoj, M.J. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl.), 2006, 186(1), 93-98.
[http://dx.doi.org/10.1007/s00213-006-0358-7] [PMID: 16575552]
[70]
Sanches, R.F.; de Lima Osório, F.; Dos Santos, R.G.; Macedo, L.R.; Maia-de-Oliveira, J.P.; Wichert-Ana, L.; de Araujo, D.B.; Riba, J.; Crippa, J.A.; Hallak, J.E. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J. Clin. Psychopharmacol., 2016, 36(1), 77-81.
[http://dx.doi.org/10.1097/JCP.0000000000000436] [PMID: 26650973]
[71]
de Araujo, D.B.; Ribeiro, S.; Cecchi, G.A.; Carvalho, F.M.; Sanchez, T.A.; Pinto, J.P.; de Martinis, B.S.; Crippa, J.A.; Hallak, J.E.; Santos, A.C. Seeing with the eyes shut: neural basis of enhanced imagery following Ayahuasca ingestion. Hum. Brain Mapp., 2012, 33(11), 2550-2560.
[http://dx.doi.org/10.1002/hbm. 21381] [PMID: 21922603]
[72]
Bouso, J.C.; Palhano-Fontes, F.; Rodríguez-Fornells, A.; Ribeiro, S.; Sanches, R.; Crippa, J.A.; Hallak, J.E.; de Araujo, D.B.; Riba, J. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur. Neuropsychopharmacol., 2015, 25(4), 483-492.
[http://dx.doi.org/10.1016/j. euroneuro.2015.01.008] [PMID: 25637267]
[73]
Palhano-Fontes, F.; Andrade, K.C.; Tofoli, L.F.; Santos, A.C.; Crippa, J.A.; Hallak, J.E.; Ribeiro, S.; de Araujo, D.B. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One, 2015, 10(2), e0118143.
[http://dx.doi.org/10.1371/journal.pone.0118143] [PMID: 25693169]
[74]
de Castro-Neto, E.F.; da Cunha, R.H.; da Silveira, D.X.; Yonamine, M.; Gouveia, T.L.; Cavalheiro, E.A.; Amado, D. Naffah-Mazzacoratti, Mda.G. Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World J. Biol. Chem., 2013, 4(4), 141-147.
[http://dx.doi.org/10.4331/wjbc.v4.i4.141] [PMID: 24340137]
[75]
Domínguez-Clavé, E.; Soler, J.; Elices, M.; Pascual, J.C.; Álvarez, E.; de la Fuente Revenga, M.; Friedlander, P.; Feilding, A.; Riba, J. Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Res. Bull., 2016, 126(Pt 1), 89-101.
[http://dx.doi.org/ 10.1016/j.brainresbull.2016.03.002] [PMID: 26976063]
[76]
Barbanoj, M.J.; Riba, J.; Clos, S.; Giménez, S.; Grasa, E.; Romero, S. Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology (Berl.), 2008, 196(2), 315-326.
[http://dx.doi.org/10.1007/s00213-007-0963-0] [PMID: 18030450]
[77]
Luke, D. Discarnate entities and N,N-dimethyltryptamine (DMT): Psychopharmacology, phenomenology and ontology Soc. Psychical. Res., 2011, 75(902[1]; 1), 26-42.
[78]
Davis, M.; Bear, H.D. Effects of N-N-dimethyltryptamine on retention of startle response habituation in the rat. Psychopharmacology (Berl.), 1972, 27(1), 29-44.
[http://dx.doi.org/10.1007/BF00421954] [PMID: 5081369]
[79]
Davis, M.; Sheard, M.H. Biphasic dose-response effects of N-N-dimethyltryptamine on the rat startle reflex. Pharmacol. Biochem. Behav., 1974, 2(6), 827-829.
[http://dx.doi.org/10.1016/0091-3057 (74)90116-6] [PMID: 4533618]
[80]
Freedland, C.S.; Mansbach, R.S. Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture. Drug Alcohol Depend., 1999, 54(3), 183-194.
[http://dx.doi.org/10.1016/S0376-8716(98)00154-9] [PMID: 10372792]
[81]
Morgenstern, J.; Langenbucher, J.; Labouvie, E.W. The generalizability of the dependence syndrome across substances: an examination of some properties of the proposed DSM-IV dependence criteria. Addiction, 1994, 89(9), 1105-1113.
[http://dx.doi.org/10.1111/j. 1360-0443.1994.tb02787.x] [PMID: 7987187]
[82]
Fantegrossi, W.E.; Woods, J.H.; Winger, G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav. Pharmacol., 2004, 15(2), 149-157.
[http://dx.doi.org/10.1097/00008877-200403000-00007] [PMID: 15096915]
[83]
Cole, J.M.; Pieper, W.A. the effects of N,N-dimenthyltryptamine on operant behaviour in squirrel monkeys. Psychopharmacology (Berl.), 1973, 16, 107-112.
[http://dx.doi.org/10.1007/BF00422642]
[84]
Gillin, J.C.; Cannon, E.; Magyar, R.; Schwartz, M.; Wyatt, R.J. Failure of N,N-dimethyltryptamine to evoke tolerance in cats. Biol. Psychiatry, 1973, 7(3), 213-220.
[PMID: 4519415]
[85]
Kovacic, B.; Domino, E.F. Tolerance and limited cross-tolerance to the effects of N, N-dimethyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) on food-rewarded bar pressing in the rat. J. Pharmacol. Exp. Ther., 1976, 197(3), 495-502.
[PMID: 1064726]
[86]
Callaway, J.C.; Airaksinen, M.M.; McKenna, D.J.; Brito, G.S.; Grob, C.S. Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology (Berl.), 1994, 116(3), 385-387.
[http://dx.doi.org/10.1007/BF02245347] [PMID: 7892432]
[87]
Strassman, R.J.; Qualls, C.R. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch. Gen. Psychiatry, 1994, 51(2), 85-97.
[http://dx.doi.org/10.1001/archpsyc.1994.03950020009001] [PMID: 8297216]
[88]
Airaksinen, M.M.; Lecklin, A.; Saano, V.; Tuomisto, L.; Gynther, J. Tremorigenic effect and inhibition of tryptamine and serotonin receptor binding by beta-carbolines. Pharmacol. Toxicol., 1987, 60(1), 5-8.
[http://dx.doi.org/10.1111/j.1600-0773.1987.tb01711.x] [PMID: 3562389]
[89]
Louis, E.D.; Zheng, W.; Jurewicz, E.C.; Watner, D.; Chen, J.; Factor-Litvak, P.; Parides, M. Elevation of blood beta-carboline alkaloids in essential tremor. Neurology, 2002, 59(12), 1940-1944.
[http://dx.doi.org/10.1212/01.WNL.0000038385.60538.19] [PMID: 12499487]
[90]
Bouso, J.C.; Fábregas, J.M.; Antonijoan, R.M.; Rodríguez-Fornells, A.; Riba, J. Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharmacology (Berl.), 2013, 230(3), 415-424.
[http://dx.doi.org/10.1007/s00213-013-3167-9] [PMID: 23793226]
[91]
Checkley, S.A.; Murray, R.M.; Oon, M.C.; Rodnight, R.; Birley, J.L. A longitudinal study of urinary excretion of N,N,-dimethyltryptamine in psychotic patients. Br. J. Psychiatry, 1980, 137, 236-239.
[http://dx.doi.org/10.1192/bjp.137.3.236] [PMID: 6777009]
[92]
Gillin, J.C.; Kaplan, J.; Stillman, R.; Wyatt, R.J. The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. Am. J. Psychiatry, 1976, 133(2), 203-208.
[http://dx.doi.org/10.1176/ajp.133.2.203] [PMID: 1062171]
[93]
Paterson, N.E.; Darby, W.C.; Sandhu, P.S.N. N-Dimethyltryptamine-induced psychosis. Clin. Neuropharmacol., 2015, 38(4), 141-143.
[http://dx.doi.org/10.1097/WNF.0000000000000078] [PMID: 26166234]
[94]
Warren, J.M.; Dham-Nayyar, P.; Alexander, J. Recreational use of naturally occurring dimethyltryptamine--contributing to psychosis? Aust. N. Z. J. Psychiatry, 2013, 47(4), 398-399.
[http://dx.doi.org/10.1177/0004867412462749] [PMID: 23047957]
[95]
Szmulewicz, A.G.; Valerio, M.P.; Smith, J.M. Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report. Int. J. Bipolar Disord., 2015, 3, 4.
[http://dx.doi.org/10. 1186/s40345-014-0020-y] [PMID: 25713771]
[96]
Flory, J.D.; Manuck, S.B.; Perel, J.M.; Muldoon, M.F. A comparison of d, l-fenfluramine and citalopram challenges in healthy adults. Psychopharmacology (Berl.), 2004, 174(3), 376-380.
[http://dx.doi.org/10.1007/s00213-003-1763-9] [PMID: 14997271]
[97]
Mas, M.; Farré, M.; de la Torre, R.; Roset, P.N.; Ortuño, J.; Segura, J.; Camí, J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J. Pharmacol. Exp. Ther., 1999, 290(1), 136-145.
[PMID: 10381769]
[98]
Davydova, S.M.; Cheido, M.A.; Gevorgyan, M.M. Effects of 5-HT2A receptor stimulation and blocking on immune response. Bull. Exp. Biol. Med., 2010, 150, 219-221.
[99]
dos Santos, R.G. Immunological effects of ayahuasca in humans. J. Psychoactive Drugs, 2014, 46(5), 383-388.
[http://dx.doi.org/10. 1080/02791072.2014.960113] [PMID: 25364989]
[100]
Frecska, E.; Szabo, A.; Winkelman, M.J.; Luna, L.E.; McKenna, D.J. A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. J. Neural Transm. (Vienna), 2013, 120(9), 1295-1303.
[http://dx.doi.org/ 10.1007/s00702-013-1024-y] [PMID: 23619992]
[101]
Szabo, A.; Kovacs, A.; Frecska, E.; Rajnavolgyi, E.; Psychedelic, N. N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One, 2014, 9(8), e106533.
[http://dx.doi.org/10.1371/journal.pone. 0106533] [PMID: 25171370]
[102]
Szabo, A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. Front. Immunol., 2015, 6, 358.
[http://dx.doi.org/10.3389/fimmu.2015.00358] [PMID: 26236313]
[103]
House, R.V.; Thomas, P.T.; Bhargava, H.N. Comparison of the hallucinogenic indole alkaloids ibogaine and harmaline for potential immunomodulatory activity. Pharmacology, 1995, 51(1), 56-65.
[http://dx.doi.org/10.1159/000139317] [PMID: 7568345]
[104]
Rosenberg, D.E.; Isbell, H.; Miner, E.J. Comparison of a placebo, N,N-dimethyltryptamine, and 6-hydroxy-N-dimethyltryptamine in man. Psychopharmacology (Berl.), 1963, 4, 39-42.
[http://dx.doi.org/10.1007/BF00429362] [PMID: 14050410]
[105]
Rosenberg, D.E.; Isbell, H.; Miner, E.J.; Logan, C.R. The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacology (Berl.), 1964, 5, 217-227.
[http://dx.doi.org/10.1007/BF00413244] [PMID: 14138757]
[106]
Bitsios, P.; Szabadi, E.; Bradshaw, C.M. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology (Berl.), 1999, 143(3), 286-292.
[http://dx.doi.org/10.1007/s002130050949] [PMID: 10353432]
[107]
Hartley, T.R.; Lovallo, W.R.; Whitsett, T.L. Cardiovascular effects of caffeine in men and women. Am. J. Cardiol., 2004, 93(8), 1022-1026.
[http://dx.doi.org/10.1016/j.amjcard.2003.12.057] [PMID: 15081447]
[108]
Pitol, D.L.; Siéssere, S.; Dos Santos, R.G.; Rosa, M.L.; Hallak, J.E.; Scalize, P.H.; Pereira, B.F.; Iyomasa, M.M.; Semprini, M.; Riba, J.; Regalo, S.C. Ayahuasca alters structural parameters of the rat aorta. J. Cardiovasc. Pharmacol., 2015, 66(1), 58-62.
[http://dx.doi.org/10.1097/FJC.0000000000000243] [PMID: 25714595]
[109]
Mahmoudian, M.; Jalilpour, H.; Salehian, P. Toxicity of Peganum harmala: Review and a case report. Iranian J. Pharmacol. Ther., 2002, 1, 1-4.
[110]
Glennon, R.A.; Dukat, M.; Grella, B.; Hong, S.; Costantino, L.; Teitler, M.; Smith, C.; Egan, C.; Davis, K.; Mattson, M.V. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend., 2000, 60(2), 121-132.
[http://dx.doi.org/10.1016/S0376-8716(99)00148-9] [PMID: 10940539]
[111]
Chen, X.; Cromer, B.A.; Lynch, J.W. Molecular determinants of β-carboline inhibition of the glycine receptor. J. Neurochem., 2009, 110(5), 1685-1694.
[http://dx.doi.org/10.1111/j.1471-4159.2009. 06273.x] [PMID: 19619142]
[112]
Pic-Taylor, A.; da Motta, L.G.; de Morais, J.A.; Junior, W.M. Santos, Ade.F.; Campos, L.A.; Mortari, M.R.; von Zuben, M.V.; Caldas, E.D. Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat. Behav. Processes, 2015, 118, 102-110.
[http://dx.doi.org/10. 1016/j.beproc.2015.05.004] [PMID: 26049017]
[113]
Sklerov, J.; Levine, B.; Moore, K.A.; King, T.; Fowler, D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J. Anal. Toxicol., 2005, 29(8), 838-841.
[http://dx.doi.org/10.1093/jat/29.8.838] [PMID: 16356341]
[114]
Warren, R.J. Fatal nicotine intoxication resulting from the ingestion of “ayahuasca”. J. Anal. Toxicol., 2004, 28, 287.
[115]
Dos Santos, R.G. Toxicity of chronic ayahuasca administration to the pregnant rat: how relevant it is regarding the human, ritual use of ayahuasca? Birth Defects Res. B Dev. Reprod. Toxicol., 2010, 89(6), 533-535.
[http://dx.doi.org/10.1002/bdrb.20272] [PMID: 21136499]
[116]
Oliveira, C.D.; Moreira, C.Q.; de Sá, L.R. Spinosa, Hde.S.; Yonamine, M. Maternal and developmental toxicity of ayahuasca in Wistar rats. Birth Defects Res. B Dev. Reprod. Toxicol., 2010, 89(3), 207-212.
[http://dx.doi.org/10.1002/bdrb.20244] [PMID: 20549682]
[117]
Gardner, D.; Riet-Correa, F.; Lemos, D.; Welch, K.; Pfister, J.; Panter, K. Teratogenic effects of Mimosa tenuiflora in a rat model and possible role of N-methyl- and N,N-dimethyltryptamine. J. Agric. Food Chem., 2014, 62(30), 7398-7401.
[http://dx.doi.org/ 10.1021/jf5005176] [PMID: 24689494]
[118]
Riba, J.; McIlhenny, E.H.; Valle, M.; Bouso, J.C.; Barker, S.A. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test. Anal., 2012, 4(7-8), 610-616.
[http://dx.doi.org/10.1002/dta.1344] [PMID: 22514127]
[119]
Herraiz, T.; González, D.; Ancín-Azpilicueta, C.; Arán, V.J.; Guillén, H. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem. Toxicol., 2010, 48(3), 839-845.
[http://dx.doi.org/10.1016/j.fct.2009.12.019] [PMID: 20036304]
[120]
Gaujac, A.; Navickiene, S.; Collins, M.I.; Brandt, S.D.; de Andrade, J.B. Analytical techniques for the determination of tryptamines and β-carbolines in plant matrices and in psychoactive beverages consumed during religious ceremonies and neo-shamanic urban practices. Drug Test. Anal., 2012, 4(7-8), 636-648.
[http://dx.doi.org/10.1002/dta.1343] [PMID: 22577086]
[121]
Callaway, J.C. Various alkaloid profiles in decoctions of Banisteriopsis caapi. J. Psychoactive Drugs, 2005, 37(2), 151-155.
[http://dx.doi.org/10.1080/02791072.2005.10399796] [PMID: 16149328]
[122]
McIlhenny, E.H.; Pipkin, K.E.; Standish, L.J.; Wechkin, H.A.; Strassman, R.; Barker, S.A. Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography-electrospray ionization-tandem mass spectrometry. J. Chromatogr. A, 2009, 1216(51), 8960-8968.
[http://dx.doi.org/10.1016/j.chroma.2009.10.088] [PMID: 19926090]
[123]
McKenna, D.J.; Towers, G.H.; Abbott, F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. J. Ethnopharmacol., 1984, 10(2), 195-223.
[http://dx.doi.org/10.1016/0378-8741(84) 90003-5] [PMID: 6587171]
[124]
Wang, Y.H.; Samoylenko, V.; Tekwani, B.L.; Khan, I.A.; Miller, L.S.; Chaurasiya, N.D.; Rahman, M.M.; Tripathi, L.M.; Khan, S.I.; Joshi, V.C.; Wigger, F.T.; Muhammad, I. Composition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson’s disease. J. Ethnopharmacol., 2010, 128(3), 662-671.
[http://dx.doi.org/10.1016/j.jep.2010.02.013] [PMID: 20219660]
[125]
Misra, P.; Khaliq, T.; Dixit, A.; SenGupta, S.; Samant, M.; Kumari, S.; Kumar, A.; Kushawaha, P.K.; Majumder, H.K.; Saxena, A.K.; Narender, T.; Dube, A. Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: an approach for rational drug design. J. Antimicrob. Chemother., 2008, 62(5), 998-1002.
[http://dx.doi.org/10.1093/jac/dkn319] [PMID: 18694906]
[126]
Carbonaro, T.M.; Gatch, M.B. Neuropharmacology of N,N-dimethyltryptamine. Brain Res. Bull., 2016, 126(Pt 1), 74-88.
[http://dx.doi.org/10.1016/j.brainresbull.2016.04.016] [PMID: 27126737]
[127]
Saavedra, J.M.; Axelrod, J. Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science, 1972, 175(4028), 1365-1366.
[http://dx.doi.org/10.1126/science.175. 4028.1365] [PMID: 5059565]
[128]
Fontanilla, D.; Johannessen, M.; Hajipour, A.R.; Cozzi, N.V.; Jackson, M.B.; Ruoho, A.E. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science, 2009, 323(5916), 934-937.
[http://dx.doi.org/ 10.1126/science.1166127] [PMID: 19213917]
[129]
Keiser, M.J.; Setola, V.; Irwin, J.J.; Laggner, C.; Abbas, A.I.; Hufeisen, S.J.; Jensen, N.H.; Kuijer, M.B.; Matos, R.C.; Tran, T.B.; Whaley, R.; Glennon, R.A.; Hert, J.; Thomas, K.L.; Edwards, D.D.; Shoichet, B.K.; Roth, B.L. Predicting new molecular targets for known drugs. Nature, 2009, 462(7270), 175-181.
[http://dx.doi.org/10.1038/nature08506] [PMID: 19881490]
[130]
Carbonaro, T.M.; Eshleman, A.J.; Forster, M.J.; Cheng, K.; Rice, K.C.; Gatch, M.B. The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice. Psychopharmacology (Berl.), 2015, 232(1), 275-284.
[http://dx.doi.org/10.1007/s00213-014-3658-3] [PMID: 24985890]
[131]
Strassman, R.J.; Qualls, C.R.; Berg, L.M. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol. Psychiatry, 1996, 39(9), 784-795.
[http://dx.doi.org/10.1016/0006-3223(95)00200-6] [PMID: 8731519]
[132]
Bunzow, J.R.; Sonders, M.S.; Arttamangkul, S.; Harrison, L.M.; Zhang, G.; Quigley, D.I.; Darland, T.; Suchland, K.L.; Pasumamula, S.; Kennedy, J.L.; Olson, S.B.; Magenis, R.E.; Amara, S.G.; Grandy, D.K. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol., 2001, 60(6), 1181-1188.
[http://dx.doi.org/10.1124/mol.60. 6.1181] [PMID: 11723224]
[133]
Premont, R.T.; Gainetdinov, R.R.; Caron, M.G. Following the trace of elusive amines. Proc. Natl. Acad. Sci. USA, 2001, 98(17), 9474-9475.
[http://dx.doi.org/10.1073/pnas.181356198] [PMID: 11504935]
[134]
Schenberg, E.E. Ayahuasca and cancer treatment. SAGE Open Med., 2013, 1, 2050312113508389.
[http://dx.doi.org/10.1177/2050312113508389] [PMID: 26770688]
[135]
Tittarelli, R.; Mannocchi, G.; Pantano, F.; Romolo, F.S. Recreational use, analysis and toxicity of tryptamines. Curr. Neuropharmacol., 2015, 13(1), 26-46.
[http://dx.doi.org/10.2174/1570159 X13666141210222409] [PMID: 26074742]
[136]
Langer, S.Z.; Lee, C.R.; Segonzac, A.; Tateishi, T.; Esnaud, H.; Schoemaker, H.; Winblad, B. Possible endocrine role of the pineal gland for 6-methoxytetrahydro-beta-carboline, a putative endogenous neuromodulator of the [3H]imipramine recognition site. Eur. J. Pharmacol., 1984, 102(2), 379-380.
[http://dx.doi.org/10.1016/0014-2999(84)90275-9] [PMID: 6090167]
[137]
Frison, G.; Favretto, D.; Zancanaro, F.; Fazzin, G.; Ferrara, S.D. A case of beta-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract. Forensic Sci. Int., 2008, 179(2-3), e37-e43.
[http://dx.doi.org/10.1016/j.forsciint.2008.05.003] [PMID: 18603389]
[138]
Anderson, B.T. Ayahuasca as antidepressant? Psychedelics and styles of reasoning in psychiatry. Anthropol. Consciousness, 2012, 23(1), 44-59.
[http://dx.doi.org/10.1111/j.1556-3537.2012.01056.x]
[139]
Rodd, R. Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela. J. Psychoactive Drugs, 2008, 40(3), 301-307.
[http://dx.doi.org/10.1080/02791072. 2008.10400645] [PMID: 19004422]
[140]
Brierley, D.I.; Davidson, C. Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 39(2), 263-272.
[http://dx.doi.org/10.1016/j.pnpbp.2012.06.001] [PMID: 22691716]
[141]
Drucker, G.; Raikoff, K.; Neafsey, E.J.; Collins, M.A. Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Res., 1990, 509(1), 125-133.
[http://dx.doi.org/10.1016/0006-8993(90)90318-6] [PMID: 2137718]
[142]
Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C.J.; McLauchlan, H.; Klevernic, I.; Arthur, J.S.; Alessi, D.R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update. Biochem. J., 2007, 408(3), 297-315.
[http://dx.doi.org/10.1042/BJ20070797] [PMID: 17850214]
[143]
Husbands, S.M.; Glennon, R.A.; Gorgerat, S.; Gough, R.; Tyacke, R.; Crosby, J.; Nutt, D.J.; Lewis, J.W.; Hudson, A.L. beta-carboline binding to imidazoline receptors. Drug Alcohol Depend., 2001, 64(2), 203-208.
[http://dx.doi.org/10.1016/S0376-8716(01)00123-5] [PMID: 11543990]
[144]
Hopp, K.H.; Cunningham, L.V.; Bromel, M.C.; Schermeister, L.J.; Khalil, S.K. In vitro antitrypanosomal activity of certain alkaloids against Trypanosoma lewisi. Lloydia, 1976, 39(5), 375-377.
[PMID: 798093]
[145]
Li, Y.; Sattler, R.; Yang, E.J.; Nunes, A.; Ayukawa, Y.; Akhtar, S.; Ji, G.; Zhang, P.W.; Rothstein, J.D. Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacology, 2011, 60(7-8), 1168-1175.
[http://dx.doi.org/10.1016/j.neuropharm.2010.10.016] [PMID: 21034752]
[146]
Schwarz, M.J.; Houghton, P.J.; Rose, S.; Jenner, P.; Lees, A.D. Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. Pharmacol. Biochem. Behav., 2003, 75(3), 627-633.
[http://dx.doi.org/10.1016/S0091-3057(03)00129-1] [PMID: 12895680]
[147]
Brierley, D.I.; Davidson, C. Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell. J. Psychopharmacol. (Oxford), 2013, 27(1), 98-108.
[http://dx.doi.org/10.1177/0269881112463125] [PMID: 23076833]
[148]
Grella, B.; Dukat, M.; Young, R.; Teitler, M.; Herrick-Davis, K.; Gauthier, C.B.; Glennon, R.A. Investigation of hallucinogenic and related beta-carbolines. Drug Alcohol Depend., 1998, 50(2), 99-107.
[http://dx.doi.org/10.1016/S0376-8716(97)00163-4] [PMID: 9649961]
[149]
Iurlo, M.; Leone, G.; Schilström, B.; Linnér, L.; Nomikos, G.; Hertel, P.; Silvestrini, B.; Svensson, H. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition. Psychopharmacology (Berl.), 2001, 159(1), 98-104.
[http://dx.doi.org/10.1007/s002130100879] [PMID: 11797076]
[150]
Schmitt, K.C.; Reith, M.E. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann. N. Y. Acad. Sci., 2010, 1187, 316-340.
[http://dx.doi.org/10.1111/j.1749-6632.2009.05148.x] [PMID: 20201860]
[151]
Adayev, T.; Wegiel, J.; Hwang, Y.W. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). Arch. Biochem. Biophys., 2011, 507(2), 212-218.
[http://dx.doi.org/10.1016/j.abb.2010.12.024] [PMID: 21185805]
[152]
Göckler, N.; Jofre, G.; Papadopoulos, C.; Soppa, U.; Tejedor, F.J.; Becker, W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J., 2009, 276(21), 6324-6337.
[http://dx.doi.org/10.1111/j.1742-4658.2009.07346.x] [PMID: 19796173]
[153]
Frost, D.; Meechoovet, B.; Wang, T.; Gately, S.; Giorgetti, M.; Shcherbakova, I.; Dunckley, T. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer’s disease-related sites. PLoS One, 2011, 6(5), e19264.
[http://dx.doi.org/10.1371/journal.pone.0019264] [PMID: 21573099]
[154]
Réus, G.Z.; Stringari, R.B.; de Souza, B.; Petronilho, F.; Dal-Pizzol, F.; Hallak, J.E.; Zuardi, A.W.; Crippa, J.A.; Quevedo, J. Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. Oxid. Med. Cell. Longev., 2010, 3(5), 325-331.
[http://dx.doi.org/10.4161/oxim.3.5.13109] [PMID: 21150338]
[155]
Callaway, J.C. Fast and slow metabolizers of Hoasca. J. Psychoactive Drugs, 2005, 37(2), 157-161.
[http://dx.doi.org/10.1080/02791072.2005.10399797] [PMID: 16149329]
[156]
Yu, A.M.; Idle, J.R.; Krausz, K.W.; Küpfer, A.; Gonzalez, F.J. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J. Pharmacol. Exp. Ther., 2003, 305(1), 315-322.
[http://dx.doi.org/10.1124/jpet.102.047050] [PMID: 12649384]
[157]
Zhao, T.; Zheng, S.S.; Zhang, B.F.; Li, Y.Y.; Bligh, S.W.; Wang, C.H.; Wang, Z.T. Metabolic pathways of the psychotropic-carboline alkaloids, harmaline and harmine, by liquid chromatography/mass spectrometry and NMR spectroscopy. Food Chem., 2012, 134(2), 1096-1105.
[http://dx.doi.org/10.1016/j.foodchem. 2012.03.024] [PMID: 23107733]
[158]
Winstock, A.R.; Kaar, S.; Borschmann, R. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. J. Psychopharmacol. (Oxford), 2014, 28(1), 49-54.
[http://dx.doi.org/10.1177/0269881113513852] [PMID: 24284475]
[159]
Gable, R.S. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction, 2004, 99(6), 686-696.
[http://dx.doi.org/10.1111/j.1360-0443.2004.00744.x] [PMID: 15139867]
[160]
Lanaro, R.; Calemi, D.B.; Togni, L.R.; Costa, J.L.; Yonamine, M. Cazenave, Sde.O.; Linardi, A. Ritualistic use of ayahuasca versus street use of similar substances seized by the police: a key factor involved in the potential for intoxications and overdose? J. Psychoactive Drugs, 2015, 47(2), 132-139.
[http://dx.doi.org/10.1080/02791072.2015.1013202] [PMID: 25950593]
[161]
Erspamer, V. Observations on the fate of indolalkylamines in the organism. J. Physiol., 1955, 127(1), 118-133.
[http://dx.doi.org/10. 1113/jphysiol.1955.sp005242] [PMID: 14354632]
[162]
Riba, J.; McIlhenny, E.H.; Bouso, J.C.; Barker, S.A. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Test. Anal., 2015, 7(5), 401-406.
[http://dx.doi.org/10.1002/dta.1685] [PMID: 25069786]
[163]
Callaway, J.C.; Grob, C.S. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J. Psychoactive Drugs, 1998, 30(4), 367-369.
[http://dx.doi.org/10.1080/02791072.1998.10399712] [PMID: 9924842]
[164]
Zhao, T.; He, Y.Q.; Wang, J.; Ding, K.M.; Wang, C.H.; Wang, Z.T. Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-carboline alkaloids, harmine derivatives. Phytother. Res., 2011, 25(11), 1671-1677.
[http://dx.doi.org/10.1002/ptr.3458] [PMID: 21433154]
[165]
Liester, M.B.; Prickett, J.I. Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions. J. Psychoactive Drugs, 2012, 44(3), 200-208.
[http://dx.doi.org/10.1080/02791072.2012. 704590] [PMID: 23061319]
[166]
Stahl, S.M. Stahl’s essential psychopharmacology: Neuroscientific basic and practical applications; Cambridge University Press: Cambridge, UK, 2008.
[167]
Glick, S.D.; Kuehne, M.E.; Raucci, J. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res., 1994, 657, 14-22.
[168]
Halpern, J.H. Hallucinogens in the treatment of alcoholism and other addictions. Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments; Winkelman, M.J; Roberts, T.B., Ed.; Praeger: Westport, CT, 2007, Vol. 2, .
[169]
Doering-Silveira, E.; Grob, C.S.; de Rios, M.D.; Lopez, E.; Alonso, L.K.; Tacla, C.; Da Silveira, D.X. Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J. Psychoactive Drugs, 2005, 37(2), 141-144.
[http://dx.doi.org/10. 1080/02791072.2005.10399794] [PMID: 16149326]
[170]
Oliveira-Lima, A.J.; Santos, R.; Hollais, A.W. Effects of ayahuasca on the development of ethanol-induced behavioral sensitization and on a post-sensitization treatment in mice. Physiol. Behav., 2015, 142, 28-36.
[171]
Aricioglu-Kartal, F.; Kayir, H.; Tayfun Uzbay, I. Effects of harman and harmine on naloxone-precipitated withdrawal syndrome in morphine-dependent rats. Life Sci., 2003, 73(18), 2363-2371.
[http://dx.doi.org/10.1016/S0024-3205(03)00647-7] [PMID: 12941438]
[172]
Miralles, A.; Esteban, S.; Sastre-Coll, A.; Moranta, D.; Asensio, V.J.; García-Sevilla, J.A. High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain. Eur. J. Pharmacol., 2005, 518(2-3), 234-242.
[http://dx.doi.org/10.1016/j.ejphar.2005.06.023] [PMID: 16061219]
[173]
Osório, Fde.L.; Sanches, R.F.; Macedo, L.R.; Santos, R.G.; Maia-de-Oliveira, J.P.; Wichert-Ana, L.; Araujo, D.B.; Riba, J.; Crippa, J.A.; Hallak, J.E. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Br. J. Psychiatry, 2015, 37(1), 13-20.
[http://dx.doi.org/10.1590/1516-4446-2014-1496] [PMID: 25806551]
[174]
Dos Santos, R.G.; Osório, F.L.; Crippa, J.A.S.; Riba, J.; Zuardi, A.W.; Hallak, J.E.C. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther. Adv. Psychopharmacol., 2016, 6(3), 193-213.
[http://dx.doi.org/10.1177/2045125316638008] [PMID: 27354908]
[175]
Santos, R.G.; Landeira-Fernandez, J.; Strassman, R.J.; Motta, V.; Cruz, A.P. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J. Ethnopharmacol., 2007, 112(3), 507-513.
[http://dx.doi.org/10.1016/j. jep.2007.04.012] [PMID: 17532158]
[176]
Farzin, D.; Mansouri, N. Antidepressant-like effect of harmane and other beta-carbolines in the mouse forced swim test. Eur. Neuropsychopharmacol., 2006, 16(5), 324-328.
[http://dx.doi.org/10. 1016/j.euroneuro.2005.08.005] [PMID: 16183262]
[177]
Fortunato, J.J.; Réus, G.Z.; Kirsch, T.R.; Stringari, R.B.; Stertz, L.; Kapczinski, F.; Pinto, J.P.; Hallak, J.E.; Zuardi, A.W.; Crippa, J.A.; Quevedo, J. Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(8), 1425-1430.
[http://dx.doi.org/10.1016/j.pnpbp.2009.07.021] [PMID: 19632287]
[178]
Fortunato, J.J.; Réus, G.Z.; Kirsch, T.R.; Stringari, R.B.; Fries, G.R.; Kapczinski, F.; Hallak, J.E.; Zuardi, A.W.; Crippa, J.A.; Quevedo, J. Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus. J. Neural Transm. (Vienna), 2010, 117(10), 1131-1137.
[http://dx.doi.org/10.1007/s00702-010-0451-2] [PMID: 20686906]
[179]
Fortunato, J.J.; Réus, G.Z.; Kirsch, T.R.; Stringari, R.B.; Fries, G.R.; Kapczinski, F.; Hallak, J.E.; Zuardi, A.W.; Crippa, J.A.; Quevedo, J. Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: further evidence of antidepressant properties. Brain Res. Bull., 2010, 81(4-5), 491-496.
[http://dx.doi.org/10.1016/j.brainresbull. 2009.09.008] [PMID: 19772900]
[180]
Osório, F.L.; de Macedo, L.R.H.; de Sousa, J.P.M.; Pinto, J. Quevedo. J.; Crippa, J.A.d.S.; Hallak, J.C.E. The therapeutic potential of harmine and ayahuasca in depression: Evidence from exploratory animal and human studies. The ethnopharmacology of ayahuasca; dos Santos, R.G., Ed.; Transworld Research Network: Kerala, India, 2011, pp. 75-85.
[181]
Samoylenko, V.; Rahman, M.M.; Tekwani, B.L.; Tripathi, L.M.; Wang, Y.H.; Khan, S.I.; Khan, I.A.; Miller, L.S.; Joshi, V.C.; Muhammad, I. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease. J. Ethnopharmacol., 2010, 127(2), 357-367.
[http://dx.doi.org/10.1016/j.jep.2009.10.030] [PMID: 19879939]
[182]
Urani, A.; Roman, F.J.; Phan, V.L.; Su, T.P.; Maurice, T. The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J. Pharmacol. Exp. Ther., 2001, 298(3), 1269-1279.
[PMID: 11504830]
[183]
Wang, J.; Mack, A.L.; Coop, A.; Matsumoto, R.R. Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice. Eur. Neuropsychopharmacol., 2007, 17(11), 708-716.
[http://dx.doi.org/10.1016/j.euroneuro.2007.02.007] [PMID: 17376658]
[184]
Piletz, J.E.; Zhu, H.; Ordway, G.; Stockmeier, C.; Dilly, G.; Reis, D.; Halaris, A. Imidazoline receptor proteins are decreased in the hippocampus of individuals with major depression. Biol. Psychiatry, 2000, 48(9), 910-919.
[http://dx.doi.org/10.1016/S0006-3223(00) 00892-1] [PMID: 11074229]
[185]
Finn, D.P.; Martí, O.; Harbuz, M.S.; Vallès, A.; Belda, X.; Márquez, C.; Jessop, D.S.; Lalies, M.D.; Armario, A.; Nutt, D.J.; Hudson, A.L. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl.), 2003, 167(2), 195-202.
[http://dx.doi.org/10.1007/s00213-003-1392-3] [PMID: 12652345]
[186]
Halaris, A.; Piletz, J.E. Relevance of imidazoline receptors and agmatine to psychiatry: A decade of progress. A. N. Y. Acad. Sci., 2003, 1009, 1-20.
[187]
Paterson, L.M.; Robinson, E.S.; Nutt, D.J.; Hudson, A.L. In vivo estimation of imidazoline(2) binding site turnover. Ann. N. Y. Acad. Sci., 2003, 1009, 367-370.
[http://dx.doi.org/10.1196/annals.1304. 049] [PMID: 15028614]
[188]
García-Sevilla, J.A.; Escribá, P.V.; Guimón, J. Imidazoline receptors and human brain disorders. Ann. N. Y. Acad. Sci., 1999, 881, 392-409.
[http://dx.doi.org/10.1111/j.1749-6632.1999.tb09388.x] [PMID: 10415944]
[189]
Bouayed, J.; Rammal, H.; Soulimani, R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid. Med. Cell. Longev., 2009, 2(2), 63-67.
[http://dx.doi.org/10.4161/oxim.2.2.7944] [PMID: 20357926]
[190]
Jacob, M.S.; Presti, D.E. Endogenous psychoactive tryptamines reconsidered: An anxiolytic role for dimethyltryptamine Med Hypothesis,2005, 64(5), 930-937. Hypothesis, 2005, 64(5), 930-937.
[http://dx.doi.org/10.1016/j.mehy.2004.11.005]
[191]
Sarris, J.; McIntyre, E.; Camfield, D.A. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs, 2013, 27(4), 301-319.
[http://dx.doi.org/10.1007/s40263-013-0059-9] [PMID: 23653088]
[192]
Santos, R.G.; Landeira-Fernandez, J.; Strassman, R.J.; Motta, V.; Cruz, A.P. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J. Ethnopharmacol., 2007, 112(3), 507-513.
[http://dx.doi.org/10.1016/j.jep.2007.04.012] [PMID: 17532158]
[193]
Graeff, F.G.; Guimarães, F.S.; De Andrade, T.G.; Deakin, J.F. Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav., 1996, 54(1), 129-141.
[http://dx.doi.org/10.1016/0091-3057(95)02135-3] [PMID: 8728550]
[194]
Metzner, R. Hallucinogenic drugs and plants in psychotherapy and shamanism. J. Psychoactive Drugs, 1998, 30(4), 333-341.
[http://dx.doi.org/10.1080/02791072.1998.10399709] [PMID: 9924839]
[195]
Nutt, D.J.; King, L.A.; Nichols, D.E. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat. Rev. Neurosci., 2013, 14(8), 577-585.
[http://dx.doi.org/10.1038/nrn3530] [PMID: 23756634]
[196]
Dos Santos, R.G.; Balthazar, F.M.; Bouso, J.C.; Hallak, J.E.C. The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. J. Psychopharmacol. (Oxford), 2016, 30(12), 1230-1247.
[http://dx.doi.org/10.1177/0269881116652578] [PMID: 27287824]
[197]
Heise, C.W.; Brooks, D.E. Ayahuasca exposure: Descriptive analysis of calls to US poison control centers from 2005 to 2015. J. Med. Toxicol., 2017, 13, 245-248.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 2
Year: 2019
Page: [108 - 128]
Pages: 21
DOI: 10.2174/1570159X16666180125095902

Article Metrics

PDF: 94
HTML: 16
EPUB: 1
PRC: 1